Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115


Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.

Palechor-Ceron N, Krawczyk E, Dakic A, Simic V, Yuan H, Blancato J, Wang W, Hubbard F, Zheng YL, Dan H, Strome S, Cullen K, Davidson B, Deeken JF, Choudhury S, Ahn PH, Agarwal S, Zhou X, Schlegel R, Furth PA, Pan CX, Liu X.

Cells. 2019 Oct 27;8(11). pii: E1327. doi: 10.3390/cells8111327. Review.


Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer.

Saenz FR, Ory V, Schmidt MO, Kallakury BV, Mueller SC, Furth PA, Wellstein A, Riegel AT.

Neoplasia. 2019 Oct;21(10):963-973. doi: 10.1016/j.neo.2019.07.001. Epub 2019 Aug 19.


Peroxisome proliferator-activated receptor gamma and BRCA1.

Furth PA.

Endocr Relat Cancer. 2018 Nov 1. pii: ERC-18-0449.R1. doi: 10.1530/ERC-18-0449. [Epub ahead of print] Review.


Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.

Alothman SJ, Wang W, Chao S, Kallakury BV, Díaz-Cruz ES, Furth PA.

Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299. No abstract available.


Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing.

Alamri AM, Liu X, Blancato JK, Haddad BR, Wang W, Zhong X, Choudhary S, Krawczyk E, Kallakury BV, Davidson BJ, Furth PA.

Dis Model Mech. 2018 Jan 29;11(1). pii: dmm031716. doi: 10.1242/dmm.031716.


The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.

Ory V, Kietzman WB, Boeckelman J, Kallakury BV, Wellstein A, Furth PA, Riegel AT.

Breast Cancer Res Treat. 2018 May;169(1):47-57. doi: 10.1007/s10549-017-4649-y. Epub 2018 Jan 19.


Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus.

Alothman SJ, Wang W, Goerlitz DS, Islam M, Zhong X, Kishore A, Azhar RI, Kallakury BV, Furth PA.

Cancer Prev Res (Phila). 2017 Apr;10(4):244-254. doi: 10.1158/1940-6207.CAPR-16-0268. Epub 2017 Mar 10.


Primary cancer cell culture: mammary-optimized vs conditional reprogramming.

Alamri AM, Kang K, Groeneveld S, Wang W, Zhong X, Kallakury B, Hennighausen L, Liu X, Furth PA.

Endocr Relat Cancer. 2016 Jul;23(7):535-54. doi: 10.1530/ERC-16-0071. Epub 2016 Jun 7.


Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.


The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Bae WK, Yoo KH, Lee JS, Kim Y, Chung IJ, Park MH, Yoon JH, Furth PA, Hennighausen L.

Mol Carcinog. 2015 Oct;54(10):1172-80. doi: 10.1002/mc.22188. Epub 2014 Jul 7.


Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction.

Mahmoodzadeh S, Leber J, Zhang X, Jaisser F, Messaoudi S, Morano I, Furth PA, Dworatzek E, Regitz-Zagrosek V.

J Cell Sci Ther. 2014 Jan 30;5(1):153. doi: 10.4172/2157-7013.1000153.


Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation.

Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R, Collins SP, Haddad N, Kallakury BV, Schroeder T, Pishvaian MJ, Furth PA.

Front Oncol. 2014 May 9;4:102. doi: 10.3389/fonc.2014.00102. eCollection 2014.


Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland.

Okolowsky N, Furth PA, Hamel PA.

Dev Biol. 2014 Jul 15;391(2):219-29. doi: 10.1016/j.ydbio.2014.04.007. Epub 2014 Apr 21.


Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.

Assefnia S, Kang K, Groeneveld S, Yamaji D, Dabydeen S, Alamri A, Liu X, Hennighausen L, Furth PA.

Endocr Relat Cancer. 2014 May 6;21(3):443-57. doi: 10.1530/ERC-14-0032. Print 2014 Jun.


Genetically engineered ERα-positive breast cancer mouse models.

Dabydeen SA, Furth PA.

Endocr Relat Cancer. 2014 May 6;21(3):R195-208. doi: 10.1530/ERC-13-0512. Print 2014 Jun. Review.


The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ.

Ory V, Tassi E, Cavalli LR, Sharif GM, Saenz F, Baker T, Schmidt MO, Mueller SC, Furth PA, Wellstein A, Riegel AT.

Oncogene. 2014 Jun 5;33(23):3033-42. doi: 10.1038/onc.2013.263. Epub 2013 Jul 15.


STAT signaling in different breast cancer sub-types.

Furth PA.

Mol Cell Endocrinol. 2014 Jan 25;382(1):612-615. doi: 10.1016/j.mce.2013.03.023. Epub 2013 Apr 3. Review.


Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer.

Nakles RE, Millman SL, Cabrera MC, Johnson P, Mueller S, Hoppe PS, Schroeder T, Furth PA.

J Vis Exp. 2013 Feb 8;(72). pii: 50198. doi: 10.3791/50198.


Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.

Furth PA.

Ann N Y Acad Sci. 2012 Oct;1271:1-9. doi: 10.1111/j.1749-6632.2012.06736.x. Review.


Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.

Miermont AM, Cabrera MC, Frech SM, Nakles RE, Diaz-Cruz ES, Shiffert MT, Furth PA.

Anat Physiol. 2012 Jun 25;Suppl 12. pii: 001.


The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.


Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer.

Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC.

Breast Cancer Res. 2011 Oct 12;13(5):220. doi: 10.1186/bcr2921. Review.


Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA.

Cancer Res. 2011 Aug 15;71(16):5477-87. doi: 10.1158/0008-5472.CAN-10-4652.


Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Furth PA, Cabrera MC, Díaz-Cruz ES, Millman S, Nakles RE.

Ann N Y Acad Sci. 2011 Jul;1229:147-55. doi: 10.1111/j.1749-6632.2011.06086.x. Review.


BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA.

Breast Dis. 2010;32(1-2):85-97. doi: 10.3233/BD-2010-0308. Review.


Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Nakles RE, Shiffert MT, Díaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, Riegel AT, Furth PA.

Mol Endocrinol. 2011 Apr;25(4):549-63. doi: 10.1210/me.2010-0114. Epub 2011 Feb 3.


Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Díaz-Cruz ES, Furth PA.

Cancer Res. 2010 May 15;70(10):3965-74. doi: 10.1158/0008-5472.CAN-09-3450.


Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD.

Cheema A, Knights CD, Rao M, Catania J, Perez R, Simons B, Dakshanamurthy S, Kolukula VK, Tilli M, Furth PA, Albanese C, Avantaggiati ML.

J Cell Physiol. 2010 Nov;225(2):371-84. doi: 10.1002/jcp.22224.


Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.

Miermont AM, Parrish AR, Furth PA.

Carcinogenesis. 2010 Jun;31(6):1124-31. doi: 10.1093/carcin/bgq048. Epub 2010 Feb 24.


Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Kleinberg DL, Wood TL, Furth PA, Lee AV.

Endocr Rev. 2009 Feb;30(1):51-74. doi: 10.1210/er.2008-0022. Epub 2008 Dec 15. Review. Erratum in: Endocr Rev. 2012 Dec;33(6):1038.


The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A, Furth PA, Riegel AT.

Cancer Res. 2008 May 15;68(10):3697-706. doi: 10.1158/0008-5472.CAN-07-6702.


Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound.

Tilli MT, Parrish AR, Cotarla I, Jones LP, Johnson MD, Furth PA.

BMC Cancer. 2008 Jan 23;8:21. doi: 10.1186/1471-2407-8-21.


Real-time imaging and characterization of human breast tissue by reflectance confocal microscopy.

Tilli MT, Cabrera MC, Parrish AR, Torre KM, Sidawy MK, Gallagher AL, Makariou E, Polin SA, Liu MC, Furth PA.

J Biomed Opt. 2007 Sep-Oct;12(5):051901.


Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA.

Oncogene. 2008 Jan 31;27(6):794-802. Epub 2007 Jul 23.


BAX regulates follicular endowment in mice.

Greenfeld CR, Pepling ME, Babus JK, Furth PA, Flaws JA.

Reproduction. 2007 May;133(5):865-76.


Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.

Genome Biol. 2007;8(5):R76.


BAX is involved in regulating follicular growth, but is dispensable for follicle atresia in adult mouse ovaries.

Greenfeld CR, Babus JK, Furth PA, Marion S, Hoyer PB, Flaws JA.

Reproduction. 2007 Jan;133(1):107-16.


Effects of ERalpha overexpression on female reproduction in mice.

Tomic D, Frech MS, Babus JK, Symonds D, Furth PA, Koos RD, Flaws JA.

Reprod Toxicol. 2007 Apr-May;23(3):317-25. Epub 2006 Aug 30.


What do shifts in indicators of apoptosis indicate about the cancer process?

Furth PA, Halama ED.

J Nutr. 2006 Oct;136(10):2700S-3S. No abstract available.


Methoxychlor induces atresia of antral follicles in ERalpha-overexpressing mice.

Tomic D, Frech MS, Babus JK, Gupta RK, Furth PA, Koos RD, Flaws JA.

Toxicol Sci. 2006 Sep;93(1):196-204. Epub 2006 Jun 20.


Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.

Katiyar P, Ma Y, Fan S, Pestell RG, Furth PA, Rosen EM.

Nucl Recept Signal. 2006;4:e006. Epub 2006 Apr 28.


Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice.

Bachelier R, Xu X, Li C, Qiao W, Furth PA, Lubet RA, Deng CX.

Oncol Rep. 2005 Nov;14(5):1117-20.


The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, Rosen EM.

Mol Endocrinol. 2006 Jan;20(1):14-34. Epub 2005 Aug 18.


PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.

Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA.

Oncogene. 2005 Apr 14;24(16):2715-22.


Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.

Jones LP, Li M, Halama ED, Ma Y, Lubet R, Grubbs CJ, Deng CX, Rosen EM, Furth PA.

Oncogene. 2005 May 19;24(22):3554-62.


Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ.

Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, Flaws JA, Furth PA.

Cancer Res. 2005 Feb 1;65(3):681-5.

Supplemental Content

Loading ...
Support Center